Institute for Molecular Medicine Finland

Labcyte and the University of Helsinki's Institute for Molecular Medicine Finland have expanded their partnership to include multiple new applications.

The pharma company will analyze genomic and clinical data from 2 million individuals over the next 10 years to drive drug development across its entire portfolio. 

NEW YORK (GenomeWeb News) – Studies by two independent research teams published online yesterday in Nature Neuroscience suggest a single gene — the enzyme-coding gene called TOP3B — contributes to processes related to schizophrenia and to a syndrome associated with autism spectrum disord

NEW YORK (GenomeWeb News) – Labcyte said today that the Institute for Molecular Medicine Finland, known as FIMM, will use Labcyte's acoustic liquid handling technology in its small molecule-based personalized cancer medicine programs, under a new collaboration.

The company's Multiplexing Diagnostics division will use the arrayer to develop molecular tools, including protein biomarkers, to diagnose allergy and autoimmunity.

The program will consist of miniaturized RNAi screens, and in the future will include compound/drug arrays.

FIMM studies cancer, as well as cardiovascular, neuro-psychiatric and viral diseases, carries out translational research, and seeks to promote human health through research on personalized medicine.

The Nordic nation will invest in a pan-European pilot program for cultivating informatics, biobanking, and translational research.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.